GGrantIndex
← Leaderboards

Rbhs-New Jersey Medical School

Newark, NJ

Compare ↔
$468,314,652
Total funding
412
Grants

Funding over time

peak $57.1M · FY2009–22
$100M$75M$50M$25M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$463,500,703 · 410
CDC$5,114,950 · 3

By mechanism

R01$309,311,823 · 191
U19$42,133,485 · 23
U01$26,753,882 · 6
R21$25,885,862 · 81
S10$7,658,892 · 10
P01$7,085,040 · 16

Investigators at Rbhs-New Jersey Medical School

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Cameron Amadeus Myhrvold$892,7212 gr2Padmapriya Banada$145,9571 gr

Emerging Leaders

6–10 yrs in

1Thomas Dick$10,669,8904 gr2Yosuke Kumamoto$6,366,0254 gr3Stanley H Weiss$3,782,3401 gr4Tessa Bergsbaken$3,346,2663 gr5Vincenzo Carnevale$2,494,1162 gr6David Rotella$1,892,5262 gr7Naoki Sawada$1,590,0001 gr8Michinari Nakamura$1,570,0001 gr

All-Time

Most funded here, all years

1Thomas Dick$10,669,8904 gr2Yosuke Kumamoto$6,366,0254 gr3Selvakumar Subbian$5,686,3595 gr4Stanley H Weiss$3,782,3401 gr5Joel Stephen Freundlich$3,765,0304 gr6Tessa Bergsbaken$3,346,2663 gr7Vincenzo Carnevale$2,494,1162 gr8David Rotella$1,892,5262 gr

Largest grants

Center to develop therapeutic countermeasures to high-threat bacterial agents$5,504,272
U19 · FY2016 · AI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,504,272
U19 · FY2017 · AI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,399,115
U19 · FY2014 · AI
Center to develop therapeutic countermeasures to high-threat bacterial agents$5,254,272
U19 · FY2015 · AI
FEND for TB$4,167,230
U01 · FY2022 · AI
FEND for TB$3,998,028
U01 · FY2020 · AI
FEND for TB$3,954,651
U01 · FY2021 · AI
Modernization and Transformation of the New Jersey Medical School Central Researc$3,821,762
C06 · FY2010 · RR
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,665,571
U19 · FY2019 · AI
Carotid Revascularization Endarterectomy vs. Stenting Trial: Long Term Follow-up$3,601,411
U01 · FY2014 · NS
Discovery and validation of a new long noncoding RNA as a novel target for neuropathic pain$3,464,207
RF1 · FY2019 · NS
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$3,457,326
U19 · FY2020 · AI
Key Facility Upgrades for the Rutgers University RBL.$3,328,439
G20 · FY2021 · AI
Center to develop therapeutic countermeasures to high-threat bacterial agents$3,306,934
U19 · FY2018 · AI
Carotid Revascularization Endarterectomy vs. Stenting Trial: Long Term Follow-up$3,015,984
U01 · FY2013 · NS
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$2,947,908
P01 · FY2014 · AI
Strategies for Eliciting bnAbs against Conserved HIV-1 Quaternary Epitopes$2,909,196
P01 · FY2013 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,751,534
U19 · FY2021 · AI
Bacterial and Host Heterogeneity in TB latency, persistence and progression$2,658,286
U19 · FY2022 · AI
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis$2,399,184
U19 · FY2018 · AI